Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, and Monoclonal and Polyclonal Antibodies Research.
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery
Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models
Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy
Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity
Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas
Immunoengineering approaches for cytokine therapy
Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours
Prolonged residence of an albumin–IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis
Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin‐10 in Murine Models
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Recruitment of CD103 <sup>+</sup> dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy
The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing
Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy
Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies
Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events